| Packard Center for ALS Research at Johns Hopkins |
| Brain Science Institute Announces License Agreement to Develop New Treatments for Neurological DiseaseMarch 12, 2010- Johns Hopkins University’s newly formed Brain Science Institute’s NeuroTranslational Program has entered into a licensing agreement with pharmaceutical company Eisai Inc. to discover and develop small molecule glutamate carboxypeptidase II (GCPII) inhibitors. The NeuroTranslational Program was launched in 2009 staffed with seasoned drug-discovery scientists to work side by side with Johns Hopkins faculty to help translate basic science discoveries into small molecule therapeutics. | Events |
 | © 2010, The Robert Packard Center for ALS Research at Johns Hopkins. All rights reserved. |
